Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Merck Announces China Erbitux Approval for Head and Neck Cancer

publication date: Mar 2, 2020

Merck KGaA of Germany announced China approval of Erbitux® to treat patients with head and neck cancer. Last year, Erbitux was granted its first approval by China's NMPA for RAS wild-type metastatic colorectal cancer. The new indication of the EFGR drug is for first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in combination with platinum-based therapy. In 1998, Merck acquired global marketing rights to Erbitux from Lilly outside of the US and Canada. More details...

Stock Symbol: (DE: MRK) (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.